Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMDNI-caged-L-glutamate
Discontinued Product
This product has been withdrawn from sale and is superseded by MNI-caged-L-glutamate (Cat. No. 1490)
Description: Stable photoreleaser of L-glutamate
Alternative Names: caged MDNI glutamate,DNI glutamate,DNI-GLU
Chemical Name: (S)-α-Amino-2,3-dihydro-4-methoxy-5,7-dinitro-δ-oxo-1H-indole-1-pentanoic acid
Purity: ≥98% (HPLC)
Biological Activity for MDNI-caged-L-glutamate
Rapidly and efficiently releases glutamate (Cat. No. 0218) when photolysed (350 - 365 nm excitation). Water soluble and stable at neutral pH, and pharmacologically inactive at neuronal glutamate receptors (up to 200 μM). 5.5 times more photosensitive than MNI-caged L-glutamate (Cat. No. 1490). Laser activation of MDNI-glu evokes a rapid increase in intracellular Ca2+ concentration in astrocytes.
Important information for MDNI-caged-L-glutamate
As a result of the manufacturing process, this product contains some residual TFA. The amount of TFA is batch dependant and will appear in the batch molecular formula.
Technical Data for MDNI-caged-L-glutamate
| M. Wt | 368.3 |
| Formula | C14H16N4O8 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 864085-92-7 |
| PubChem ID | 124221751 |
| InChI Key | SYNWQVVPBORTQE-QMMMGPOBSA-N |
| Smiles | O=C(CC[C@H](N)C(O)=O)N1C2=C([N+]([O-])=O)C=C([N+]([O-])=O)C(OC)=C2CC1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for MDNI-caged-L-glutamate
References for MDNI-caged-L-glutamate
References are publications that support the biological activity of the product.
Fedoryak et al (2005) Synthesis of a caged glutamate for efficient one- and two-photon photorelease on living cells. Chem. Commun. (Camb.) 7 3664 PMID: 16027904
Papageorgiou et al (2005) Synthetic and photochemical studies of substituted 1-acyl-7-nitroindolines. Photochem.Photobiol.Sci. 4 887 PMID: 16252044
Popovic et al (2015) Electrical behaviour of dendritic spines as revealed by voltage imaging. Nat.Commun. 6 8436 PMID: 26436431
View Related Products by Target
Keywords: MDNI-caged-L-glutamate, MDNI-caged-L-glutamate supplier, Stable, photoreleaser, L-glutamate, Caged, Compounds, Glutamate, mGlur, Receptors, Metabotropic, Non-Selective, iGlur, Ionotropic, agonists, MNI, glutamate, MNI-Glutamate, caged, MDNI, DNI, DNI-GLU, Miscellaneous, Non-selective, mGlu, 5785, Tocris Bioscience
Citations for MDNI-caged-L-glutamate
Citations are publications that use Tocris products.
Currently there are no citations for MDNI-caged-L-glutamate.
Reviews for MDNI-caged-L-glutamate
There are currently no reviews for this product. Be the first to review MDNI-caged-L-glutamate and earn rewards!
Have you used MDNI-caged-L-glutamate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.